In addition to outcome and treatment assignment: Baseline auxiliary covariates
• Demographic , physiologic characteristics
• Prior treatment and medical history
• Baseline measure(s) of the outcome
Reasons for Covariate Adjustment
Ordinarily: Inferences on treatment comparisons based only on data on outcome and treatment assignment "Covariate adjustment:" with auxiliary baseline covariates has been advocated
• to account for chance imbalances in baseline covariates
• to gain efficiency
• Extensive literature : Senn (1989), Hauck et al. (1998) , Koch et al. (1998) , Tangen and Koch (1999) , Pocock et al. (2002) , . . .
• Extensive concerns : Potential bias due to post hoc (subjective ) selection of covariates to use, and. . .
• . . . temptation to engage in a "fishing expedition " for the most dramatic effect
• ⇒ Trialists and regulatory authorities reluctant to endorse
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Covariate Adjustment
Standard approach to adjustment: Direct regression modeling
• Model outcome as a function of treatment assignment and covariates
• ⇒ Inextricable link between parameters involved in treatment comparisons and the "adjustment "
Our objective: A general methodology for using auxiliary covariates that leads to more efficient estimators
• Based on the theory of semiparametrics (e.g., Tsiatis, 2006) • Separates parameters involved in treatment comparisons from the "adjustment ". . .
• . . . and hence leads to a principled approach to implementation that can obviate the usual concerns
. . , n, (iid) where for patient i
• Y i response variable (discrete, continuous, longitudinal, censored)
• Z i denotes treatment assignment (For simplicity we will consider only two treatments, but methods generalize easily to more than two treatments)
• X i denotes other baseline covariates measured prior to randomization
• Here the parameter of interest is β =Log-odds ratio for treatments 1 and 0
Unconditional Inference
Example 3: Time to event (censored data)
• Here the data are represented as
-As before Z i is treatment indicator and X i denotes baseline covariates
where λ(t|Z) denotes the conditional hazard rate of failing at time t given treatment Z
• The parameter of interest is β=Log-hazard ratio for treatments 1 and 0
Conditional versus unconditional inference
Focus of inference: Comparisons based on β are unconditional
• Treatment effect averaged across the population
Alternative: Comparison conditional on subset of the population with X = x; e.g., in Example 1
• OLS estimator for φ is consistent for β regardless
• ANCOVA is used for covariate adjustment (direct regression modeling )
• Conditional vs. unconditional not a big deal
Conditional vs. unconditional is a big deal: E.g., binary outcome
Similarly: time to event outcome
• Unconditional model
Debate: Which is more clinically relevant ?
• Most trials: unconditional primary analysis
• ⇒ We focus on unconditional inference
Semiparametric model
In general: β is the parameter relevant to making (unconditional ) treatment comparisons in an assumed model for the conditional distribution of Y given Z
• Possibly additional parameter α
• η is an additional nuisance parameter needed to describe fully the class of densities being assumed
• η null in fully parametric models
• η infinite-dimensional in nonparametric or semiparametric models
• Fully parametric model (e.g., logistic model for binary response)
• Semiparametric model (e.g., proportional hazards model for time to event outcome)
Semiparametric model for all of (Y, X, Z): Class of joint densities
Goal: Consistent and asymptotically normal estimators for β based on
. . , n, iid making no assumptions beyond this semiparametric model
• Inclusion of X ⇒ "covariate adjustment "
Semiparametric theory
Approach: Derive estimators by characterizing the class of all estimating functions for θ (and hence β) leading to estimators for θ that are consistent and asymptotically normal under the semiparametric model
• Estimating function : Function of a single observation and parameters that can be used to construct estimating equations leading to estimators for the parameters
• ⇒ We seek unbiased estimating functions for θ depending on (Y, Z, X) (lead to consistent and asymptotically normal estimators );
• Corresponding estimator is solution to
Estimating functions without auxiliary covariates
Start by considering unbiased estimating functions depending on (Y, Z) only:
yields OLS estimator for β ⇒ β OLS = difference in sample means
yields logistic regression MLE, also log-odds ratio of sample proportions
For the Proportional hazards model of Example 3, the parameter β is estimated by maximizing the partial likelihood or solving the estimating equation
where
Estimating functions using auxiliary covariates
Main result: For a given semiparametric model members of the class of all unbiased estimating functions for θ using all of (Y, Z, X) may be written
• m(Y, Z; θ) is a fixed unbiased estimating function for θ without auxiliary covariates
• a(X) is an arbitrary function of X
• a(X) ≡ 0 ⇒ "unadjusted estimator " θ = ( β, α)
• "Augmentation term " effects the "adjustment "
• By Z⊥ ⊥X, augmentation term has mean zero ⇒ unbiased Adjusted estimator for θ:
• Judicious choice of a(X) ⇒ improved efficiency over the "unadjusted " estimator θ
Estimating functions using auxiliary covariates
Optimal estimating function in the class: Elements of the estimator have smallest asymptotic variance
• Optimal estimating equation
• E{m(Y, Z; θ) | X, Z = g}, g = 0, 1 are unknown functions of X ⇒ model them. . .
Implementation
Approach: Adaptive algorithm
and obtain ζ g by OLS separately (3) For each i = 1 . . . , n, form predicted values q g (X i , ζ g ) for each g = 0, 1 and solve in θ with π = n
Implementation Properties: From semiparametric theory
• With the regression models q g as above, θ is guaranteed relatively more efficient than θ, even if q g incorrect
• θ is consistent and asymptotically normal regardless of q g
• If the q g models are exactly correct ⇒ θ is asymptotically equivalent to the optimal estimator if we knew E{m(Y, Z; θ) | X, Z = g} Implementation By-product:
• The "adjustment " for X is determined separately by treatment group. . .
• . . . and regression modeling is carried out independently of β
• ⇒ Can develop models without concerns over subjectivity "Principled" strategy:
• Regression modeling for each g = 0, 1 based on data for i ∈ g only may be carried out by separate analysts for each g. . .
• . . . different from those who calculate θ (and hence β)
Standard errors: For θ and hence β
• θ is an M-estimator
• ⇒ Sandwich method for asymptotic variance for β Implementation Special case: Example 1 (continuous response Y )
• All estimators for β are asymptotically equivalent to
where Y g denotes treatment-specific sample average for treatment g = (0, 1)
• In this class : ANCOVA, ANCOVA with treatment-covariate interaction , Koch et al. (1998)'s "nonparametric " estimator,. . .
• Optimal estimator takes
See Tsiatis et al. (2008) Simulations 1. Binary response: 5000 Monte Carlo data sets, n = 200 logit{E(Y |Z)} = α + βZ
• P (Z = 1) = P (Z = 0) = 0.5
• Generate Y as Bernoulli with
α g chosen to yield mild , moderate , or strong association between Y and X for each g (R 2 = 0.12, 0.25, 0.34)
• Unadjusted estimate via logistic regression MLE
• Adjusted estimates via "direct approach " with different choices for
Augmentations:" 
In order to generate data where
• the distribution of T given Z follows a proportional hazards model
• T and X are correlated
• X and Z are independent 1. We generate bivariate data (V, X) from a bivariate normal density with mean zero, variance 1 , and correlation ρ 2. Independently generate treatment indicator Z as a Bernoulli (π) 3. Let T = − exp(−βZ) log{1 − Φ(V )}, where Φ(·) is the cumulative distribution function (CDF) of a standard normal 4. Censoring was generated as an independent exponential distribution C ∼ Exp(c).
Simulations
• Treatment was assigned with π = .5
• the correlation of V and X was ρ = .7 which resulted in roughly a correlation of 0.6 between T and X
• We took β = 0 (null hypothesis) and β = .25
• The value c for the exponential distribution of the censoring variable that would result in roughly 25% of the data being censored
• Sample sizes of 250 and 600 were considered Simulations "Estimators considered:"
• β PH : Unadjusted estimator using MPLE from unconditional model
fit by OLS
• β REG : We also considered the estimator φ obtained by considering the Cox regression model
Note: This is not the true conditional model • A randomized study of 2139 patients with HIV disease to four antiretroviral regimes
• treatment 0 (Zidovudine, 532 patients) treatment 1 (Zidovudine and didanosine, 522 patients), treatment 2 (Zidovudine and zalcitabine, 524 patients ) and treatment 3 (Didanosine, 561 patients)
• The primary endpoint was a combined endpoint corresponding to the first time that a patient had a ≥ 50 percent decline in their CD4 cell count, an event indicating progression to the acquired immunodeficiency syndrome (AIDS), or death.
• Roughly 76% of the data were censored, almost all administrative censoring.
Example
• A comparison was made between treatment 0 (control) versus treatments 1,2, and 3 respectively
• We also considered several prognostic baseline auxiliary covariates including CD4, CD8, age (years), weight (kg), history of IV drug use (0=no, 1=yes), Karnofsky score (on a scale of 0-100), Zidovudine in the 30 days prior to 175 (0=no, 1=yes), number of days pre-175 antiretroviral therapy and symptomatic indicator (0=asymp, 1=symp)
Figure 1: Log negative log survival function of time to death for each treatment Example 
Discussion
• General approach to using baseline auxiliary covariates to improve efficiency of estimators and theory can also be applied to tests
• General measures of treatment effect
• Arises naturally via semiparametric theory
• Even when regression adjustment leads to improved estimators of unconditional treatment effect (i.e., linear models) there is a tension between gains in efficiency and compromised analysis
• Incorporation of covariate information separated from evaluation of treatment effects
• Impact of model selection
• Can be extended to k-arm trials and missing data
